Computational tools for polypharmacology and repurposing J Achenbach, P Tiikkainen, L Franke, E Proschak Future medicinal chemistry 3 (8), 961-968, 2011 | 96 | 2011 |
Estimating error rates in bioactivity databases P Tiikkainen, L Bellis, Y Light, L Franke Journal of chemical information and modeling 53 (10), 2499-2505, 2013 | 75 | 2013 |
Analysis of commercial and public bioactivity databases P Tiikkainen, L Franke Journal of chemical information and modeling 52 (2), 319-326, 2012 | 60 | 2012 |
Critical comparison of virtual screening methods against the MUV data set P Tiikkainen, P Markt, G Wolber, J Kirchmair, S Distinto, A Poso, ... Journal of chemical information and modeling 49 (10), 2168-2178, 2009 | 53 | 2009 |
Learning conditional variational autoencoders with missing covariates S Ramchandran, G Tikhonov, O Lönnroth, P Tiikkainen, H Lähdesmäki Pattern Recognition 147, 110113, 2024 | 17 | 2024 |
Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens P Tiikkainen, A Poso, O Kallioniemi Journal of computer-aided molecular design 23, 227-239, 2009 | 14 | 2009 |
Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910. Na JHE Mäki-Jouppila, LJ Laine, J Rehnberg, E Narvi, P Tiikkainen, ... Molecular cancer therapeutics 13 (5), 1054-1066, 2014 | 10 | 2014 |
Distinct gene expression profiles in adult rat brains after acute MK-801 and cocaine treatments M Storvik, P Tiikkainen, M van Iersel, G Wong European neuropsychopharmacology 16 (3), 211-219, 2006 | 7 | 2006 |
Study of ligand-based virtual screening tools in computer-aided drug design P Tiikkainen Annales Universitatis Turkuensis D 897, 2010 | 6 | 2010 |
VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro LJ Laine, JHE Mäki-Jouppila, E Kutvonen, P Tiikkainen, TKM Nyholm, ... Oncoscience 8, 134, 2021 | 2 | 2021 |
VTT-006, a novel anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro L Laine, J Maki-Jouppila, E Kutvonen, P Tiikkainen, T Nyholm, J Tien, ... MOLECULAR BIOLOGY OF THE CELL 25, 2014 | | 2014 |
Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712 P Tiikkainen, L Franke EP Patent 2,792,359, 2014 | | 2014 |
Discovery of Novel Anti-Mitotic Compounds Targeting Hec1 L Laine, JH Maki-Jouppila, A Kukkonen-Macchi, T Nyholm, P Tiikkainen, ... MOLECULAR BIOLOGY OF THE CELL 22, 2011 | | 2011 |
High-throughput siRNA screening reveals candidate therapeutic targets for clinically aggressive breast cancers, including several genes in the HER-2 amplicon K Kleivi, K Hellstrom, H Edgren, S Haapa-Paananen, M Wolf, S Pollari, ... Cancer Research 68 (9_Supplement), 918-918, 2008 | | 2008 |
A link between multiple high throughput technology datasets E Bucher, P Kohonen, V Fey, J Mpindi, H Sara, T Pisto, H Edgren, ... 9th International Conference on Systems Biology, ICSB2008, 186, 2008 | | 2008 |
High-throughput gene silencing in breast cancer by RNAi reveals functional taxonomies and identifies candidate drug targets overexpressed in highly proliferative clinical … K Kleivi, S Haapa-Paananen, H Edgren, M Wolf, S Pollari, N Salhberg, ... Cancer Research 67 (9_Supplement), 4955-4955, 2007 | | 2007 |
RNA interference profiles, gene expression, and copy number changes in bone metastatic breast cancer cells: an integrated molecular and functional screening S Pollari, M Perälä, S Haapa-Paananen, N Sahlberg, K Ojala, ... Cancer Research 66 (8_Supplement), 978-978, 2006 | | 2006 |
Structural/Ligand and Cell-based High-throughput Screens for Identification of Allosteric PLK1 Inhibitors J Rehnberg, M Vuoriluoto, P Halonen, P Tiikkainen, N Sahlberg, M Perala, ... MOLECULAR BIOLOGY OF THE CELL 17, 2006 | | 2006 |
Adverse event prediction using a task-specific generative model O Lönnroth, S Ramchandran, P Tiikkainen, M Öğretir, J Leinonen, ... ICML 3rd Workshop on Interpretable Machine Learning in Healthcare (IMLH), 0 | | |